Eli Lilly (LLY)
918.12
+0.62 (0.07%)
NYSE · Last Trade: Mar 20th, 10:01 AM EDT
Detailed Quote
| Previous Close | 917.50 |
|---|---|
| Open | 910.55 |
| Bid | 917.52 |
| Ask | 919.00 |
| Day's Range | 910.55 - 921.50 |
| 52 Week Range | 623.78 - 1,133.95 |
| Volume | 731,631 |
| Market Cap | 878.26B |
| PE Ratio (TTM) | 40.01 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.75%) |
| 1 Month Average Volume | 2,919,404 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
These companies have impressive track records of navigating the biggest challenges in their industry.
Via The Motley Fool · March 20, 2026
Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.
Via The Motley Fool · March 20, 2026
Both have plenty to offer investors, but one has a better outlook.
Via The Motley Fool · March 19, 2026
Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.
Via The Motley Fool · March 19, 2026
Volatility in the stock market often leads to great long-term opportunities for investors.
Via The Motley Fool · March 19, 2026
Eli Lilly says retatrutide trial results show major weight loss and blood sugar improvements in the diabetes study.
Via Benzinga · March 19, 2026

I am not turned off by the company's recent setbacks.
Via The Motley Fool · March 19, 2026
Patients taking retatrutide, lost 16.8% of their body weight over 40 weeks.
Via Investor's Business Daily · March 19, 2026
The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based company fell nearly 4% during the session, trading in the range of $211 to $219, a stark contrast to the
Via MarketMinute · March 18, 2026

Hut 8 operates large-scale data centers supporting Bitcoin mining and high-performance computing for institutional clients.
Via The Motley Fool · March 18, 2026
Eli Lilly shares made a large move lower. But they are oversold and getting close to a level where there may be support.
Via Benzinga · March 18, 2026
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from its consolidation ambitions. Instead, strategic buyers have evolved, trading the broad "mega-merger" attempts of the past for targeted,
Via MarketMinute · March 18, 2026
As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year characterized by regulatory uncertainty and legal skirmishes, the company’s stock staged a breathtaking 50%+ rally in the first two weeks of March. This [...]
Via Finterra · March 18, 2026
Airlines Take Flight While Oil Burns: Markets Edge Higher Amid Middle East Tensionschartmill.com
Via Chartmill · March 18, 2026
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. Looking ...
Via StockStory · March 17, 2026
Each of these companies could benefit from this high-growth market over time.
Via The Motley Fool · March 17, 2026
These companies are benefiting from a tidal wave of demand for new weight-loss drugs.
Via The Motley Fool · March 17, 2026

Today, March 17, 2026, selective tech gains helped lift the Nasdaq even as oil prices and geopolitical tensions stayed elevated.
Via The Motley Fool · March 17, 2026
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stoc...
Via StockStory · March 17, 2026
You don't have to go all in to profit from AI.
Via The Motley Fool · March 17, 2026
Which S&P500 stocks are moving on Tuesday?chartmill.com
Via Chartmill · March 17, 2026
The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.
Via Stocktwits · March 17, 2026

Eli Lilly's stock price is based on growth rates that might fall short.
Via The Motley Fool · March 17, 2026
Tuesday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · March 17, 2026